Anavex Life Sciences
On Wednesday, shares in New York-based Anavex Life Sciences Corp. recorded a trading volume of 1.20 million shares, which was above their three months average volume of 739,760 shares. The stock ended the session 5.78% higher at $4.76. The Company's shares have gained 20.20%, both, in the last one month and on an YTD basis, and 70.61% in the previous three months. The stock is trading 18.04% above its 50-day moving average and 15.28% above its 200-day moving average. Moreover, shares of Anavex Life Sciences, which engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers, have a Relative Strength Index (RSI) of 73.80.
On January 19th, 2017, Anavex Life Sciences and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org, announced that Rettsyndrome.org has committed a financial grant of a minimum of $0.6 million to cover the majority of a planned US multicenter Phase-2 clinical trial of ANAVEX 2-73 for the treatment of Rett syndrome. Scheduled to begin in 2017, the trial will be a randomized, double blind, placebo-controlled study of ANAVEX 2-73 in patients with Rett syndrome lasting up to 12 weeks. Your complete research report on AVXL can be retrieved for free at:
Seattle, Washington-based Omeros Corp.'s stock closed the day 0.10% lower at $9.68 with a total trading volume of 329,575 shares. The Company's shares have advanced 18.05% in the previous three months. The stock is trading 7.72% below its 50-day moving average. Additionally, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 48.69.
On December 07th, 2016, Omeros announced that an abstract highlighting positive results from the ongoing OMS721 Phase-2 clinical trial in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepted for presentation at the 2017 Tandem Meeting of the American Society of Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research in Orlando, Florida. OMS721 is Omeros' lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). The title of the abstract is "Early Results of Phase-II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy" and will be presented on February 25th, 2017, by Dr. Samer Khaled, M.D., Assistant Clinical Professor of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte California and OMS721 clinical investigator. A free report on OMER is just a click away at:
Shares in Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc. recorded a trading volume of 850,751 shares, and ended yesterday's trading session 1.72% higher at $4.74. The stock has advanced 7.00%, both, in the past month and since the start of this year, and 33.90% over the previous three months. The Company's shares are trading above their 50-day moving average by 6.54%. Furthermore, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have an RSI of 60.56. Sign up for your complimentary research report on SPPI at:
The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc.'s stock finished Wednesday's session 1.26% lower at $14.15 with a total trading volume of 489,725 shares. The Company's shares have advanced 2.31%, both, in the last one month and since the start of this year. The stock is trading below its 50-day moving average by 6.19%. Additionally, shares of Lexicon Pharma, which focuses on the discovery and development of pharmaceutical products for the treatment of human diseases, have an RSI of 48.85.
On January 09th, 2017, Lexicon Pharma announced the commencement of dosing in a Phase-1 clinical trial of LX2761, an orally-delivered small molecule compound for the potential treatment of diabetes. LX2761 is an internally generated compound and is designed to inhibit SGLT1 locally in the gastrointestinal tract without any significant inhibition of SGLT2 in the kidney. Register for free on Stock-Callers.com and download the latest research report on LXRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA